• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于近期研究的非酒精性脂肪性肝病发病机制

[NAFLD pathogenesis in the light of recent research].

作者信息

Banaszczak Marcin, Stachowska Ewa

机构信息

Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Broniewskiego 24,71-460 Szczecin, Poland.

出版信息

Postepy Biochem. 2017;63(3):190-197.

PMID:29294263
Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. Nowadays, the number of people with type II diabetes and hypertension is growing. These symptoms belong to metabolic syndrome and the liver manifestation of this disease is NAFLD. Most people suffering from NAFLD are obese but this disease can also affect the lean individuals. This disease in extreme cases can lead to liver fibrosis and cirrhosis. Although NAFLD remains largely asymptomatic for the most of the time it can progress to a severe form of disease called nonalcoholic steatohepatitis (NASH) or even hepatocellular carcinoma. In this review we describe a role of factors that influence NAFLD pathogenesis such as: insulin resistance, epigenetic factors, adipokine dysfunction, intestinal flora disorder, oxidative stress and markers of inflammatory states in the form of fatty acid derivatives.

摘要

非酒精性脂肪性肝病(NAFLD)是世界上最常见的肝脏疾病之一。如今,II型糖尿病和高血压患者的数量正在增加。这些症状属于代谢综合征,而该疾病的肝脏表现就是NAFLD。大多数患有NAFLD的人都肥胖,但这种疾病也会影响体型偏瘦的个体。在极端情况下,这种疾病会导致肝纤维化和肝硬化。尽管NAFLD在大多数时候基本没有症状,但它可能会发展成一种严重的疾病形式,即非酒精性脂肪性肝炎(NASH),甚至肝细胞癌。在这篇综述中,我们描述了影响NAFLD发病机制的因素所起的作用,这些因素包括:胰岛素抵抗、表观遗传因素、脂肪因子功能障碍、肠道菌群紊乱、氧化应激以及以脂肪酸衍生物形式存在的炎症状态标志物。

相似文献

1
[NAFLD pathogenesis in the light of recent research].基于近期研究的非酒精性脂肪性肝病发病机制
Postepy Biochem. 2017;63(3):190-197.
2
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)的分子机制。
Adv Exp Med Biol. 2021;1261:223-229. doi: 10.1007/978-981-15-7360-6_20.
3
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的当前药物治疗方法。
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
4
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的组织病理学
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
5
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.利用动物模型研究非酒精性脂肪性肝炎相关的肝细胞癌。
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.
6
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
7
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?代谢综合征与非酒精性脂肪性肝病:胰岛素抵抗是其中的关联因素吗?
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:55-65. doi: 10.1016/j.mce.2015.02.018. Epub 2015 Feb 24.
8
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.瘦型非酒精性脂肪性肝病患者的肝脏和心血管损伤,及其与内脏肥胖的关系。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.
9
[Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].非酒精性脂肪性肝炎发病机制分析与防治
Nihon Eiseigaku Zasshi. 2015;70(3):197-204. doi: 10.1265/jjh.70.197.
10
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.

引用本文的文献

1
N-acetylcysteine acts as a potent anti-inflammatory agent altering the eicosanoid profile in the development of simple steatosis and its progression to hepatitis.N-乙酰半胱氨酸作为一种强效抗炎剂,在单纯性脂肪变性的发展及其向肝炎的进展过程中改变类花生酸谱。
Clin Exp Hepatol. 2023 Dec;9(4):386-395. doi: 10.5114/ceh.2023.133106. Epub 2023 Dec 5.
2
Inflammation Factors and Genistein Supplementation in Cancer-Preliminary Research.癌症中的炎症因子与补充染料木黄酮——初步研究
Curr Issues Mol Biol. 2024 Mar 7;46(3):2166-2180. doi: 10.3390/cimb46030140.
3
Impact of One-Year Dietary Education on Change in Selected Anthropometric and Biochemical Parameters in Children with Excess Body Weight.
一年饮食教育对超重儿童部分人体测量学和生物化学参数变化的影响。
Int J Environ Res Public Health. 2022 Sep 16;19(18):11686. doi: 10.3390/ijerph191811686.
4
Eicosapentaenoic acid loaded silica nanoemulsion attenuates hepatic inflammation through the enhancement of cell membrane components.负载二十碳五烯酸的二氧化硅纳米乳剂通过增强细胞膜成分减轻肝脏炎症。
Biol Proced Online. 2022 Sep 7;24(1):11. doi: 10.1186/s12575-022-00173-z.
5
Arachidonic Acid as an Early Indicator of Inflammation during Non-Alcoholic Fatty Liver Disease Development.花生四烯酸作为非酒精性脂肪性肝病发展过程中炎症的早期指标。
Biomolecules. 2020 Jul 31;10(8):1133. doi: 10.3390/biom10081133.